Previous 10 | Next 10 |
Shares of Cortexyme (NASDAQ: CRTX) , a clinical-stage biotechnology company, are collapsing in response to a clinical trial failure. Investors upset with the results had hammered the stock 74.9% lower as of 12:14 p.m. EDT on Wednesday. Cortexyme's former lead candidate, atuzagin...
Gainers: G Medical Innovations (NASDAQ:GMVD) +18%, Guardion Health Sciences (NASDAQ:GHSI) +12%, Nurix Therapeutics NRIX +11%, Privia Health (NASDAQ:PRVA) +8%, Monopar Therapeutics MNPR +7%. Losers: Cortexyme (NASDAQ:CRTX) -75%, BIMI Inter...
Gainers: Enphase Energy ENPH +12%. Tenable Holdings TENB +10%. Aware AWRE +8%. Marqeta MQ +6%. EVgo (NASDAQ:EVGOW) +583%. Losers: Cortexym CRTX -72%. Angion Biomedica ANGN -56%. DBV Technologies DBVT -28%. Redbox Entertainment (NASDAQ:RDBXW) -16%. ...
In overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline Clinical data validated ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P 500 wrapped up its best week since July, closing at its highest level in a month, as a series of upside earnings reports from Wal...
Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed. Small Pharma Analyst shares a lon...
While the S&P 500 index added ~1.8% gain over the week, its healthcare constituents underperformed with a ~0.8% rise yet, recording their first weekly gain in more than a month. Dragged down by pharma stocks, the sector became the second-worst performer in the index for ano...
Cortexyme has a unique hypothesis- that Alzheimer’s disease (AD) is caused by a neurological infection with P. gingivalis. There is a surprising amount of data generated by the company and independent labs supporting this hypothesis. The stock will likely soar if the GAIN t...
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer’s disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will participate at the upcoming 14 th Clinical Trials on Alzheimer's Disease (CTAD 2...
CRTX is pursuing a highly speculative hypothesis that gingivitis plays a role in the pathogenesis of Alzheimer's Disease (AD). Top line results for AD Phase 2/3 trial expected mid-November; success would be one of the greatest medical breakthroughs in modern history. Success in a ...
News, Short Squeeze, Breakout and More Instantly...
New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...
Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...